Skip to main content

Table 2 Cumulative activity of 131I (in GBq [mCi]) depending on the risk classification for the non metastatic patients treated by RAI before 2015 (Group 1) and since 2015 (Group 2)

From: Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

 

Group 1

Group 2

P value

n

Median

Range

n

Median

Range

All risks

46

3.70 [100]

1.11–11.1 [30–300]

38

1.11 [30]

1.11–7.4 [30–200]

< 0.001

low-risk

5

3.70 [100]

1.11–3.70 [30–100]

0

N/A

N/A

< 0.001

intermediate-risk

27

3.70 [100]

1.11–11.1 [30–300]

27

1.11 [30]

N/A

< 0.001

high-riska

14

5.55 [150]

1.85–9.25 [50–250]

11

2.67 [72]

1.11–7.4 [30–200]

< 0.001

  1. N/A not applicable, mCi millicurie, GBq gigabecquerel
  2. a patients with distant metastases are excluded
Back to article page

Thyroid Research

ISSN: 1756-6614